-

Calyxo, Inc. to Present at the 44th Annual J.P. Morgan Healthcare Conference

PLEASANTON, Calif.--(BUSINESS WIRE)--Calyxo, Inc., a medical device company advancing innovative solutions for kidney stone treatment, announced today that Joe Catanese, Ph.D., Chief Executive Officer of Calyxo will present at the J.P. Morgan 44th Annual Healthcare Conference on Monday, January 12, 2026, at 8:30 AM PT in San Francisco, CA.

“Being invited to present at the J.P. Morgan Healthcare Conference for the first time is a meaningful milestone,” said Joe Catanese. “We’ve made significant progress expanding adoption of the CVAC System and advancing our clinical evidence"

Share

“Being invited to present at the J.P. Morgan Healthcare Conference for the first time is a meaningful milestone for Calyxo and reflects the strong momentum we’ve built across our business,” said Joe Catanese. “We’ve made significant progress expanding adoption of the CVAC System, advancing our clinical evidence, and scaling our commercial footprint. I look forward to sharing how our continued focus on innovation and clinical evidence is driving growth and improving care for patients with kidney stone disease.”

About Kidney Stones

According to the American Urological Association, approximately 10% of people in the U.S. will have a kidney stone at some point in their lives. Kidney stone disease is a painful condition that can result in significant healthcare costs (Current Urology Reports estimates $4.1 billion in annual direct treatment costs by 2030).

About the CVAC System

The CVAC System was FDA-cleared in 2024 and enables a minimally invasive approach for kidney stone clearance. It is an all-in-one solution designed to efficiently and effectively remove kidney stones. It uses irrigation and vacuum aspiration to continuously clear stone fragments during and after laser lithotripsy, enabling physicians to achieve a stone-free outcome.

About Calyxo, Inc.

Calyxo, Inc. is an innovation-driven medical device company focused on improving care for patients with kidney stones by delivering paradigm-shifting solutions that enable urologists to safely, effectively and efficiently achieve unrivaled clinical outcomes. Learn more at calyxoinc.com.

“CVAC” and “Calyxo” are registered trademarks of Calyxo, Inc.

Contacts

Media Contact:
Alyssa Paldo
Alyssa.paldo@finnpartners.com
M: +1 847 791 8085

Industry:

Calyxo, Inc.

Release Versions
English

Contacts

Media Contact:
Alyssa Paldo
Alyssa.paldo@finnpartners.com
M: +1 847 791 8085

More News From Calyxo, Inc.

AUA 2026 Data Reinforce Procedural Efficiency, Stone Clearance, and Safety of the CVAC System in the Real World

PLEASANTON, Calif.--(BUSINESS WIRE)--Calyxo, Inc., a medical device company redefining kidney stone treatment, today highlighted the results from multiple studies presented at the American Urological Association (AUA) 2026 Annual Meeting evaluating the performance of the CVAC System across comparative analyses, benchtop testing, and real-world safety outcomes. Collectively, the data demonstrate consistent stone clearance, high aspiration efficiency, and safety outcomes across a broad range of c...

Calyxo Enters AUA2026 With Its Largest Clinical Evidence Presence to Date and Enhanced Visualization

PLEASANTON, Calif.--(BUSINESS WIRE)--Calyxo, Inc., a medical device company redefining kidney stone treatment, will arrive at the American Urological Association (AUA) Annual Meeting with strong clinical momentum, supported by an expanded evidence base and increasing adoption of the CVAC System in practice. At this year’s meeting, 10 abstracts, the highest number presented to date, will highlight safety, efficacy, and procedural efficiency, alongside multiple opportunities for hands-on, physici...

Calyxo Secures $40 Million Series F Financing as CVAC System Surpasses 40,000 Patients Treated for Kidney Stone Removal

PLEASANTON, Calif.--(BUSINESS WIRE)--Calyxo, Inc., a medical device company redefining kidney stone treatment, today announced the closing of a $40 million Series F financing round, led by Ally Bridge Group and Janus Henderson Investors, with continued support from Questa Capital, Avidity Partners, and CRG. The financing follows a key company milestone; 40,000 patients treated with the CVAC System. Adoption of Calyxo’s all-in-one aspiration-based stone removal system reflects increasing clinici...
Back to Newsroom